DemeRx
Miami, Florida, United States · Biotechnology, Health Care · 35 employees
DemeRx, Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to transforming addiction therapeutics and improving outcomes for individuals facing substance use disorders. Leveraging advanced scientific research and strategic clinical initiatives, DemeRx focuses on DMX-1001 (noribogaine) as a groundbreaking solution for alcohol use disorder.
Funding history
- Funding Round — $1.7M — Oct 2025
Recent signals
- Jul 07, 2026: DemeRx Appoints Michael Snitkovsky as Chief Operations Officer
- Oct 07, 2025: Raised $1.7M
See plans & pricing → Track DemeRx’s funding, hiring, and signals — with verified contacts — on Fundz.